Traws Pharma, Inc. Cash and Restricted Cash
Traws Pharma, Inc. (TRAW) had Cash and Restricted Cash of $5.02 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5.02M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.13M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.82M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.42M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $5.02M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $3.13M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $3.82M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $6.42M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $13.08M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $15.94M 10-Q · filed 2026-05-15 |
| 2024-12-31 | $21.34M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $5.41M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $16.89M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $16.39M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $20.82M 10-K · filed 2026-04-15 |
| 2023-09-30 | $25.24M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $29.73M 10-Q · filed 2024-08-15 |
| 2023-03-31 | $34.22M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $38.76M 10-K · filed 2025-03-31 |
| 2022-09-30 | $42.61M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $46.53M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $50.77M 10-Q · filed 2023-05-15 |
| 2021-12-31 | $55.07M 10-K · filed 2024-04-01 |
| 2021-09-30 | $59.38M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $43.71M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $48.01M 10-Q · filed 2022-05-13 |
| 2020-12-31 | $19.02M 10-K · filed 2023-03-30 |
| 2020-09-30 | $24.20M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $27.23M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $31.04M 10-Q · filed 2021-05-17 |
| 2020-02-29 | $32.60M 10-K · filed 2020-03-27 |
| 2020-01-03 | $32.00M 10-K · filed 2020-03-27 |
| 2019-12-31 | $22.73M 10-K · filed 2022-03-21 |
| 2019-09-30 | $4.82M 10-Q · filed 2020-11-16 |
| 2019-06-30 | $5.88M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $10.40M 10-Q · filed 2020-05-15 |
| 2018-12-31 | $16.97M 10-K · filed 2021-03-18 |
| 2018-09-30 | $22.38M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $29.54M 10-Q · filed 2019-08-14 |
| 2018-03-31 | $7.26M 10-Q · filed 2019-05-15 |
| 2017-12-31 | $4.02M 10-K · filed 2020-03-27 |
| 2017-09-30 | $7.60M 10-Q · filed 2018-11-14 |
| 2017-06-30 | $14.99M 10-Q · filed 2018-08-14 |
| 2017-03-31 | $15.39M 10-Q · filed 2018-05-15 |
| 2016-12-31 | $21.45M 10-K · filed 2019-04-01 |
| 2015-12-31 | $19.85M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |